The use of nanotechnology, like the tau-fluorophore BT-1, a BODIPY-based probe and highly specific fluorescent ligand, is another promising technique that may expand our ability to evaluate for tau in the human retina and our ability for early detection of tauopathies (Soloperto et al., 2022; Barolo et al., 2024). The gene discussed is MAPT; the disease is tauopathy.